Chapter 1. Viral Disorder and Therapeutic Approaches
1.1. Common Viral Infections
1.2. Vaccines or Antiviral Drugs
1.3. Inhibition of Viral Infection of Cells
1.4. Inhibition of Viral Processing
Chapter 2. Review of Major Viral Disorders
2.1. Human Immunodeficiency Virus
2.2. Hepatitis Viruses
Hepatitis A
Hepatitis B
Hepatitis C
2.3. Herpes Viruses
Herpes Simplex Virus
Varicella-Zoster Virus
Cytomegalovirus
Epstein-Barr Virus
2.4. Human Papilloma Virus
2.5. Respiratory Viruses
Influenza
Respiratory Syncytial Virus
Coronaviruses
Chapter 3. Current Treatment
3.1. Human Immunodeficiency Virus
HIV Reverse Transcriptase Inhibitors
HIV Protease Inhibitors
HIV Fusion Inhibitors
3.2. Hepatitis Viruses
Vaccine Treatments
Cytokines
Antiviral Agents
3.3. Herpes Viruses
Viral Replication Inhibitors
3.4. Human Papilloma Viruses
3.5. Respiratory Viruses
Vaccines
Neuraminidase Inhibitors
Antibodies
Inosine Monophosphate Dehydrogenase Inhibitors
Chapter 4. Compounds in Development: New Antiviral Agents
4.1. Human Immunodeficiency Virus
HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
Cell Entry Blockers
HIV Replication Inhibitors
HIV Integrase Inhibitors
HIV Maturation Inhibitors
Combination Therapies
4.2. Hepatitis C
HCV Protease Inhibitors
NS3 Protease Inhibitors
Polymerase Inhibitors
Immunostimulants: Interferons
Toll-like Receptor Agonists
Other Immunoregulators
Viral Replication Inhibitors
4.3. Hepatitis B
DNA Polymerase Inhibitors
Other Agents
4.4. Herpes Viruses
Vaccines
Viral Replication Inhibitors
Viral Uptake Inhibitors
DNA Synthesis Inhibitors
Other Agents
4.5. Human Papilloma Viruses
Vaccines
Interferons
Immunomodulators
4.6. Influenza
New Drugs
New Vaccines
H5N1 Influenza Vaccines
Chapter 5. Company R&D Profiles
5.1. Abbott
5.2. Achillion
5.3. Boehringer Ingelheim
5.4. Biota Holdings
5.5. Bristol-Myers Squibb
5.6. Chiron
5.7. Coley
5.8. Enzo Biochem
5.9. Gilead Sciences
5.10. GlaxoSmithKline
5.11. Hoffmann-La Roche
5.12. Idenix Pharmaceuticals
5.13. Japan Tobacco
5.14. Johnson & Johnson
5.15. Medivir
5.16. Merck & Co.
5.17. Novartis AG
5.18. Panacos Pharmaceuticals
5.19. Pfizer
5.20. sanofi pasteur
5.21. Schering-Plough
5.22. Trimeris
5.23. Valeant
5.24. Vertex
5.25. ViroPharma Incorporated
Chapter 6. EXPERT INTERVIEWS: Dr. Michael G. Cordingley, Boehringer Ingelheim (Canada) Ltd.; Dr. Stef Heylen, Tibotec; Professor Bertil Samuelsson, Medivir AB
6.1. HIV
6.2. Hepatitis
6.3. Other Viral Infections
6.4. Other Issues
References
Glossary
Company Index with Web Sites
| 
